Subscribe to RSS
DOI: 10.1055/s-2004-834800
New and Efficient Approach to Aryl Phosphoramidate Derivatives of AZT/d4T as Anti-HIV Prodrugs
Publication History
Publication Date:
20 October 2004 (online)
![](https://www.thieme-connect.de/media/synlett/200414/lookinside/thumbnails/10.1055-s-2004-834800-1.jpg)
Abstract
Ester exchange of diaryl phosphite with AZT or d4T produced aryl AZT/d4T H-phosphonate, and the following reaction with amino acid esters in the presence of hexachloroethane and triethylamine yielded membrane-soluble anti-HIV prodrugs aryl phosphoramide derivatives of AZT and d4T in good yields.
Key words
aryl phosphoramidate - anti-HIV - AZT - d4T
- 1
Mitsuya H.Weinhold KJ.Furman PA.St. Clair MH.Nusinoff-Lehrman S.Gallo RC.Bolognesi D.Barry DW.Broder S. Proc. Natl. Acad. Sci., U.S.A. 1985, 82: 7096 - 2
Mitsuya H.Broder S. Proc. Natl. Acad. Sci., U.S.A. 1986, 83: 1911 - 3
Balzarini J.Kang GJ.Dalal M.Herdewijn P.De Clercq E.Broder S.Johns DG. Mol. Pharmacol. 1987, 32: 162 - 4
Herdewijn P.Balzarini J.De Clercq E.Pauwels R.Baba M.Broder S.Vanderhaeghe H. J. Med. Chem. 1987, 30: 1270 - 5
Balzarini J.Baba M.Pauwels R.Herdewijn P.De Clercq E. Biochem. Pharmacol. 1988, 37: 2847 - 6
Jones RJ.Bischofberger W. Antiviral Res. 1995, 27: 1 - 7
Meier C. Synlett 1998, 233 - 8
McGuigan C.Devine KG.Connor TJ.Galpin SA.Jeffries DJ.Kinchington D. Antiviral Chem. Chemother. 1990, 1: 107 - 9
Farrow SN.Jones AS.Kumar A.Walker RT.Balzarini J.De Clercq E. J. Med. Chem. 1990, 33: 1400 - 10
Balzarini J.Cooney DA.Dalal M.Kang GJ.Cupp JE.De Clercq E.Broder S.Johns DG. Mol. Pharmacol. 1987, 82: 798 - 11
Starnes MC.Cheng YC. J. Biol. Chem. 1987, 262: 988 - 12
Hao Z.Cooney DA.Farquhar D.Perno CF.Zhang K.Masood R.Wilson Y.Hartman NR.Balzarini J.Johns DG. Mol. Pharmacol. 1990, 37: 157 - 13
Johnson MA.Ahluwajia G.Connelly MC.Cooney DA.Broder S.Johns DG.Fridland A. J. Biol. Chem. 1998, 263: 15354 - 14
Johnson MA.Fridland A. Mol. Pharmacol. 1989, 36: 291 - 15
Perno CF.Yarchoan R.Cooney DA.Hartman NR.Webb DSA.Hao Z.Mitsuya H.Johns DG.Broder S. J. Exp. Med. 1989, 169: 933 - 16
McGuigan C.Pathirana RN.Balzarini J.De Clercq EJ. J. Med.Chem. 1993, 36: 1048 - 17
Venkatachalam TK.Tai HL.Vig R.Chen CL.Jan ST.Uckun FM. Bioorg. Med. Chem. Lett. 1998, 8: 3121 - 18
Jones RJ.Bishofberger N. Antiviral Res. 1995, 27: 1 - 19
Stang SL.Meier R.Rocaboy C.Gladysz JA. J. Fluorine Chem. 2003, 119: 141 - 20
Walsh EN. J. Am. Chem. Soc. 1959, 81: 3023 - 22
Georgiev EM.Kaneti J.Troev K.Roundhill DM. J. Am. Chem. Soc. 1993, 115: 10964
References
Analytical data of representative compound 9ae [2′,3′-dideoxy-2′,3′-didehydrothymidine 5′-(phenyl methoxy-phenylalaninyl phosphate)]: 13P NMR (121 MHz, CDCl3): δ = 3.30, 3.70 (a pair of diastereomers, ratio of peak area = 4:6) ppm. 1H NMR (300 MHz, CDCl3): δ = 1.78 (s, 3 H, 5-Me), 2.94-2.99 (m, 2 H, CH2Ph), 3.64 (s, 3 H, OMe), 3.84-4.19 (m, 4 H, Phe-CH, Phe-NH, 2H-5′), 4.89 (m, 1 H, H-4′), 5.82-5.88 (m, 1 H, H-3′), 6.20-6.29 (m, 1 H, H-2′), 7.12-7.27 (m, 12 H, 2 Ph, H-1′, H-6), 9.43 (s, 1 H, NH) ppm. 13C NMR (75 MHz, CDCl3): δ = 12.21 (C5), 40.30 (CH2Ph), 52.29 (OCH3), 55.45, 55.73 (Phe-CH), 66.20, 66.87 (C-5′), 84.36, 84.58 (C-4′), 89.42, 89.67 (C-1′), 111.20, 111.31 (C5), 119.91, 119.98 (OPh-ortho), 125.06 (OPh-para), 127.11, 127.21 (C-2′), 128.49, 129.34, 129.63 (CH2 Ph), 129.34, 129.63 (OPh-meta), 133.18-133.50 (C-3′), 135.46 (6-C), 150.18, 150.29 (OPh-ipso), 150.86 (C2), 163.84 (C4), 172.72 (Phe-CO). ESI-MS: m/z = 542 [M + H]+, 564 [M + Na]+.